CF PharmTech (HKSE:02652) Inventories, Work In Process: HK$6.8 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02652 CF PharmTech Inc HKSE:02652
15 GF Score
Price HK$17.35
! 5 Warning Signs
View Full Analysis

What is CF PharmTech Inventories, Work In Process?

CF PharmTech HKSE:02652 +0.81% 15 Inventories, Work In Process is HK$6.8 Mil as of Dec. 2025. GuruFocus rates HKSE:02652 with a GF Score™ of 15/100. The stock has 5 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. CF PharmTech's work in process for the quarter that ended in Dec. 2025 was HK$6.8 Mil.

CF PharmTech Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for CF PharmTech's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CF PharmTech Inventories, Work In Process Chart

CF PharmTech Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
7.07 6.01 14.57 6.81

CF PharmTech Semi-Annual Data
Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process 7.07 6.01 14.57 6.81
HKSE:02652
15GF Score
CF PharmTech Inc HKSE:02652
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CF PharmTech Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of HK$6.8 Mil mean?
CF PharmTech (HKSE:02652) has a Inventories, Work In Process of HK$6.8 Mil as of Dec. 2025. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on CF PharmTech and its competitors.
Is CF PharmTech's Inventories, Work In Process too high?
CF PharmTech's current Inventories, Work In Process is HK$6.8 Mil. Overall, CF PharmTech has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does CF PharmTech's Inventories, Work In Process compare to ZTS?
CF PharmTech's Inventories, Work In Process of HK$6.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Drug Manufacturers company?
A good Inventories, Work In Process depends on the Drug Manufacturers industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on CF PharmTech and its competitors. CF PharmTech's current Inventories, Work In Process is HK$6.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CF PharmTech stock overvalued right now?
CF PharmTech (HKSE:02652) has a current Inventories, Work In Process of HK$6.8 Mil. The current Inventories, Work In Process is HK$6.8 Mil. CF PharmTech's overall GF Score™ is 15/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For CF PharmTech (HKSE:02652), the current Inventories, Work In Process is HK$6.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CF PharmTech Business Description

Address No. 16, Hucundang Road, Xiangcheng Economic Development District, Jiangsu, Suzhou, CHN
CF PharmTech Inc is engaged in inhalation drug delivery technology. It is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is a specialist in the development of complex inhalation formulations with high barriers to entry, and a platform-based pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, international regulatory filing, and commercialization. Leveraging its self-developed, globally integrated end-to-end capabilities, from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to small interfering RNA (siRNA) nucleic acid delivery platforms. Its therapeutic areas encompass respiratory diseases and nasal diseases.
15GF Score

Get the complete analysis for HKSE:02652

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$17.35
Price